As shown in Table 1, low PGM5 expression was significantly associated with lymph node metastasis (P = 0.041), clinical stage (P = 0.039) and poor survival (P = 0.005). Here, PGM5 is linked to metastatic malignant neoplasm in the lymph nodes.